Skip to search boxSkip to navigationSkip to main content

Predictors of remission and low disease activity state in systemic lupus erythematosus: Data from a multiethnic, multinational Latin American cohort

  • ,
  • D. Wojdyla
    ,
  • G. J. Pons-Estel
    ,
  • R. Quintana
    ,
  • J. A. Gómez-Puerta
    ,
  • L. J. Catoggio
  • ,
  • Universidad Científica del Sur
    ,
  • Subgerencia de Atención Preventivo Promocional y Complejidad Creciente
    ,
  • Grupo Latino Americano De Estudio de Lupus (GLADEL)
    ,
  • Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR)
    ,
  • Hospital Clinic Barcelona
Research Output:
Contribution to journal
Article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1299-1308 (10 pages)

Journal (Volume, Issue Number)

Journal of Rheumatology (Volume 46, Issue 10)

Publication milestones

  • Published - 2019

Publication status

Published - 2019

ISSN

0315-162X

Publication IDs

  • Scopus: 85072758050
  • PubMed: 30824636

Abstract

Objective. To determine the predictors of remission and low disease activity state (LDAS) in patients with systemic lupus erythematosus (SLE). Methods. Three disease activity states were defined: Remission = SLE Disease Activity Index (SLEDAI) = 0 and prednisone ≤ 5 mg/day and/or immunosuppressants (maintenance dose); LDAS = SLEDAI ≤ 4, prednisone ≤ 7.5 mg/day and/or immunosuppressants (maintenance dose); and non-optimally controlled state = SLEDAI > 4 and/or prednisone > 7.5 mg/day and/or immunosuppressants (induction dose). Antimalarials were allowed in all groups. Patients with at least 2 SLEDAI reported and not optimally controlled at entry were included in these analyses. Outcomes were remission and LDAS. Multivariable Cox regression models (stepwise selection procedure) were performed for remission and for LDAS. Results. Of 1480 patients, 902 were non-optimally controlled at entry; among them, 196 patients achieved remission (21.7%) and 314 achieved LDAS (34.8%). Variables predictive of a higher probability of remission were the absence of mucocutaneous manifestations (HR 1.571, 95% CI 1.064–2.320), absence of renal involvement (HR 1.487, 95% CI 1.067–2.073), and absence of hematologic involvement (HR 1.354, 95% CI 1.005–1.825); the use of immunosuppressive drugs before the baseline visit (HR 1.468, 95% CI 1.025–2.105); and a lower SLEDAI score at entry (HR 1.028, 95% CI 1.006–1.051 per 1-unit decrease). These variables were predictive of LDAS: older age at entry, per 5-year increase (HR 1.050, 95% CI 1.004–1.098); absence of mucocutaneous manifestations (HR 1.401, 95% CI 1.016–1.930) and renal involvement (HR 1.344, 95% CI 1.049–1.721); and lower SLEDAI score at entry (HR 1.025, 95% CI 1.009–1.042). Conclusion. Absence of mucocutaneous, renal, and hematologic involvement, use of immunosuppressive drugs, and lower disease activity early in the course of the disease were predictive of remission in patients with SLE; older age was predictive of LDAS.

Funding Details

We are grateful to Daniel Villalba and Leonardo Grasso for assistance with the ARTHROS software. The GLADEL group acknowledges PANLAR (Pan American League of Associations for Rheumatology) for its support of the SLE study group.
FundersFunding numbers
APLAR
-